clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2023-101-6-279-285clinmed-565Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL INVESTIGATIONSВариабельность ритма сердца и качество жизни у больных с метастазами рака молочной железыHeart rate variability and quality of life ın patients with breast cancer metastasisМехралиевО. Ш.MekhralievO. Sh.

Мехралиев Орудж Шамшали оглы— кандидат медицинских наук, диссертант, Научно-исследовательский центр.

AZ 1022, Баку

Oruj Shamshadin ogly Mekhraliev.

AZ 1022, Baku

АгаевА. А.AgayevA. A.

Агаев Анар Азам оглы— доктор медицинских наук, профессор кафедры общественного здоровья и организации здравоохранения.

AZ 1022, Баку

Anar Azam ogly Agayev.

AZ 1022, Baku

mic_amu@mail.ruАзербайджанский медицинский университетАзербайджанAzerbaijan Medical UniversityAzerbaijan2023200720231016279285Copyright © Мехралиев О.Ш., Агаев А.А., 20232023Мехралиев О.Ш., Агаев А.А.Mekhraliev O.S., Agayev A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/565

Внедрение в клиническую практику метода холтеровского мониторирования (ХМЭКГ) и опросников качества жизни позволяет оценить степень риска развития опасных  нарушений ритма сердца  и наиболее важных параметров, связанных  с повседневной  деятельностью  пациенток со злокачественными  новообразованиями  молочной  железы. Цель исследования. Оценка физического и психологического здоровья с учетом вариабельности сердечного  ритма у больных раком молочной железы, осложненного метастатическими поражениями  лимфатических узлов. Материал и методы. Были использованы  данные  анкетирования 115 больных раком молочной железы  и метастатическими поражениями  лимфоузлов, находившихся на лечении в Республиканской онкологической больнице, разделенных на две группы: основную — 45 больных метастатическим раком молочной железы  c поражением  лимфоузлов и контрольную — 70 пациенток без  поражений  лимфатических  узлов. Средний возраст пациенток составил  от 30 до 60 и более лет. В настоящей работе критериями при установлении показаний к проведению ХМЭКГ считались жалобы, ассоциированные с нарушениями ритма сердца. Анкетирование для определения  качества жизни было  выполнено с помощью официальных версий опросников EORTC QLQ-C30 и QLQ-C30/BR23.  Результаты. Согласно  результатам статистического анализа полученных данных оказалось, что эффективный рефрактерный период предсердий (ЭРП ПР) в основной  группе на фоне фибрилляции предсердий  (ФП) короче, чем у пациенток  контрольной  группы (р = 0,001). Также выявлено, что при диагностировании рака молочной железы помимо укорочения ЭРП ПР важным фактором является увеличение времени восстановления функции синусового  узла и его корригированного эквивалента (КВВФСУ) при относительно низких средних значениях дневной, ночной и суточной частоты сердечных сокращений. Ухудшение общего состояния или общая усталость — одни из наиболее частых симптомов, встречавшихся у пациентов с раком молочной железы. причем эти же признаки необходимо рассматривать в качестве важных параметров, значимо влияющих на показатели качества жизни пациенток, отягощенных метастатическими поражениями регионарных лимфатических узлов.

The implementation  of Holter monitoring  (HMECG)  and quality of life questionnaires  in clinical practice allows  for the assessment of the risk of developing dangerous heart rhythm disorders and the most important parameters related to the daily activities of patients with breast cancer. The aim of the study was to evaluate the physical and psychological health, taking into account the variability of heart rate in patients with breast cancer complicated by metastatic lymph node involvement. Material and methods. The study used data from questionnaires  completed by 115 breast cancer patients with metastatic lymph node involvement  who were receiving treatment at the Republican  Oncological  Hospital, divided into two groups: a main group of 45 patients with metastatic breast cancer and lymph node involvement, and a control group of 70 patients without lymph node involvement. The average age of the patients was between 30 and 60 years old. Complaints associated with heart rhythm disorders were considered as criteria for indicating HMECG. Quality of life questionnaires were performed using official versions of EORTC QLQ-C30 and QLQ-C30/BR23 questionnaires. Results. According to the results of statistical analysis, it was found that the effective refractory period of the atria (ERP PR) in the main group during atrial fibrillation (AF) was shorter than in the control group (p = 0.001). It was also found that in addition to shortening the ERP PR, an important factor in diagnosing breast cancer is an increase in the recovery time of the sinus node function and its corrected equivalent (CVVFSU) at relatively low average values of daily, nocturnal, and diurnal heart rate frequencies. Worsening overall condition or general fatigue are some of the most common symptoms encountered in breast cancer patients, which should be considered as important parameters significantly affecting the quality of life of patients burdened with metastatic regional lymph node involvement.

рак молочной железыметастазыкачество жизниопросники EORTC QLQ-C30/BR23QLQ-C30холтеровское мониторированиеритм сердцаbreast cancermetastasesquality of lifeEORTC QLQ-C30/BR23QLQ-C30Holter monitoringheart rhythmReferencesLei S., Zheng R., Zhang S., Wang S., Chen R., Sun K., Zeng H., Zhou J., Wei W. Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. Cancer Commun. (Lond). 2021;41(11):1183-1194. DOI: 10.1002/cac2.12207Lei S., Zheng R., Zhang S., Wang S., Chen R., Sun K., Zeng H., Zhou J., Wei W. Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. Cancer Commun. (Lond). 2021;41(11):1183-1194. DOI: 10.1002/cac2.12207Kim J.S., Kim J.H., Chang J.H., Kim D.W., Shin K.H. Prediction of breast cancer-related lymphedema risk after postoperative radiotherapy via multivariable logistic regression analysis. Front. Oncol. 2022;12:1026043. DOI: 10.3389/fonc.2022.1026043Kim J.S., Kim J.H., Chang J.H., Kim D.W., Shin K.H. Prediction of breast cancer-related lymphedema risk after postoperative radiotherapy via multivariable logistic regression analysis. Front. Oncol. 2022;12:1026043. DOI: 10.3389/fonc.2022.1026043Balmagambetova S., Tlegenova Z., Zholdin B., Kurmanalina G., Talipova I., Koyshybaev A., Nurmanova D., Sultanbekova G., Baspayeva M., Madinova S. et al. Early diagnosis of chemotherapy-linked cardiotoxicity in breast cancer patients using conventional biomarker panel: a prospective study protocol. Diagnostics. 2022;12:2714. DOI: 10.3390/diagnostics12112714Balmagambetova S., Tlegenova Z., Zholdin B., Kurmanalina G., Talipova I., Koyshybaev A., Nurmanova D., Sultanbekova G., Baspayeva M., Madinova S. et al. Early diagnosis of chemotherapy-linked cardiotoxicity in breast cancer patients using conventional biomarker panel: a prospective study protocol. Diagnostics. 2022;12:2714. DOI: 10.3390/diagnostics12112714Nardin S., Mora E., Varughese F.M., D'Avanzo F., Vachanaram A.R., Rossi V., Saggia C., Rubinelli S., Gennari A. Breast cancer survivorship, quality of life, and late toxicities. Front. Oncol. 2020;10:864. DOI: 10.3389/fonc.2020.00864Nardin S., Mora E., Varughese F.M., D'Avanzo F., Vachanaram A.R., Rossi V., Saggia C., Rubinelli S., Gennari A. Breast cancer survivorship, quality of life, and late toxicities. Front. Oncol. 2020;10:864. DOI: 10.3389/fonc.2020.00864Doege D., Thong M.S.Y., Koch-Gallenkamp L. et al. Clinical and sociodemographic determinants of disease-specific health-related quality of life in long-term breast cancer survivors. J. Cancer Res. Clin. Oncol. 2022;148;3461-3473. DOI: 10.1007/s00432-022-04204-wDoege D., Thong M.S.Y., Koch-Gallenkamp L. et al. Clinical and sociodemographic determinants of disease-specific health-related quality of life in long-term breast cancer survivors. J. Cancer Res. Clin. Oncol. 2022;148;3461-3473. DOI: 10.1007/s00432-022-04204-wAlquraan L., Alzoubi K.H., Rababa'h S., Karasneh R., Al-Azzam S., Al-Azayzih A. Prevalence of depression and the quality-of-life of breast cancer patients in Jordan. J. Multidiscip. Healthc. 2020;13:1455-1462. DOI: 10.2147/JMDH.S277243Alquraan L., Alzoubi K.H., Rababa'h S., Karasneh R., Al-Azzam S., Al-Azayzih A. Prevalence of depression and the quality-of-life of breast cancer patients in Jordan. J. Multidiscip. Healthc. 2020;13:1455-1462. DOI: 10.2147/JMDH.S277243de Ligt K.M., Heins M., Verloop J., Ezendam N.P.M., Smorenburg C.H., Korevaar J.C., Siesling S. The impact of health symptoms on health-related quality of life in early-stage breast cancer survivors. Breast Cancer Res. Treat. 2019;178(3):703-711. DOI: 10.1007/s10549-019-05433-3de Ligt K.M., Heins M., Verloop J., Ezendam N.P.M., Smorenburg C.H., Korevaar J.C., Siesling S. The impact of health symptoms on health-related quality of life in early-stage breast cancer survivors. Breast Cancer Res. Treat. 2019;178(3):703-711. DOI: 10.1007/s10549-019-05433-3Huang, HY., Tsai, WC., Chou, WY. et al. Quality of life of breast and cervical cancer survivors. BMC Women's Health. 2017;17:30. DOI: 10.1186/s12905-017-0387-xHuang, HY., Tsai, WC., Chou, WY. et al. Quality of life of breast and cervical cancer survivors. BMC Women's Health. 2017;17:30. DOI: 10.1186/s12905-017-0387-xHuang W., Xu R., Zhou B., Lin C., Guo Y., Xu H., Guo X. Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy. Front. Cardiovasc. Med. 2022;9:912329. DOI: 10.3389/fcvm.2022.912329Huang W., Xu R., Zhou B., Lin C., Guo Y., Xu H., Guo X. Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy. Front. Cardiovasc. Med. 2022;9:912329. DOI: 10.3389/fcvm.2022.912329Rushton M., Kappel C., Lima I., Tuna M., Pritchard K., Hawken S., Dent S. Cardiac Monitoring and Heart Failure in Advanced Breast Cancer Patients Treated With Trastuzumab in Ontario, Canada. Front. Cardiovasc. Med. 2022;19;9:850674. DOI: 10.3389/fcvm.2022.850674Rushton M., Kappel C., Lima I., Tuna M., Pritchard K., Hawken S., Dent S. Cardiac Monitoring and Heart Failure in Advanced Breast Cancer Patients Treated With Trastuzumab in Ontario, Canada. Front. Cardiovasc. Med. 2022;19;9:850674. DOI: 10.3389/fcvm.2022.850674DeLuna H., Velikov D., Patel H., Feld J., Robin J., Rosenberg C.A., Saha P. Improving cardiac monitoring in patients with early-stage breast cancer receiving cardiotoxic chemotherapy in a multidisciplinary cancer center. J. Clin. Oncol. 2022;40(28):191191. DOI: 10.1200/JCO.2022.40.28_suppl.191DeLuna H., Velikov D., Patel H., Feld J., Robin J., Rosenberg C.A., Saha P. Improving cardiac monitoring in patients with early-stage breast cancer receiving cardiotoxic chemotherapy in a multidisciplinary cancer center. J. Clin. Oncol. 2022;40(28):191191. DOI: 10.1200/JCO.2022.40.28_suppl.191Caspi I., Freund O., Biran R., Bornstein G. Holter ECG monitoring for the evaluation of stroke in the internal medicine department. J. Stroke Cerebrovasc. Dis. 2022;31(12):106802. DOI: 10.1016/j.jstrokecerebrovasdis.2022.106802Caspi I., Freund O., Biran R., Bornstein G. Holter ECG monitoring for the evaluation of stroke in the internal medicine department. J. Stroke Cerebrovasc. Dis. 2022;31(12):106802. DOI: 10.1016/j.jstrokecerebrovasdis.2022.106802Rushton M., Kappel C., Lima I., Tuna M., Pritchard K., Hawken S., Dent S. Cardiac monitoring and heart failure in advanced breast cancer patients treated with trastuzumab in Ontario, Canada. Front. Cardiovasc. Med. 2022;19;9:850674. DOI: 10.3389/fcvm.2022.850674Rushton M., Kappel C., Lima I., Tuna M., Pritchard K., Hawken S., Dent S. Cardiac monitoring and heart failure in advanced breast cancer patients treated with trastuzumab in Ontario, Canada. Front. Cardiovasc. Med. 2022;19;9:850674. DOI: 10.3389/fcvm.2022.850674Balla A., Weaver D.L. Pathologic evaluation of lymph nodes in breast cancer: contemporary approaches and clinical implications. Surg. Pathol. Clin. 2022;15(1):15-27. DOI: 10.1016/j.path.2021.11.002.Balla A., Weaver D.L. Pathologic evaluation of lymph nodes in breast cancer: contemporary approaches and clinical implications. Surg. Pathol. Clin. 2022;15(1):15-27. DOI: 10.1016/j.path.2021.11.002.Hernández-Blanquisett A., Quintero-Carreño V., Álvarez-Londoño A., Martínez-Ávila M.C., Diaz-Cáceres R. Sexual dysfunction as a challenge in treated breast cancer: in-depth analysis and risk assessment to improve individual outcomes. Front. Oncol. 2022;12:955057. DOI: 10.3389/fonc.2022.955057Hernández-Blanquisett A., Quintero-Carreño V., Álvarez-Londoño A., Martínez-Ávila M.C., Diaz-Cáceres R. Sexual dysfunction as a challenge in treated breast cancer: in-depth analysis and risk assessment to improve individual outcomes. Front. Oncol. 2022;12:955057. DOI: 10.3389/fonc.2022.955057Hoyle E., Kilbreath S., Dylke E. Body image and sexuality concerns in women with breast cancer-related lymphedema: a cross-sectional study. Support Care Cancer. 2022;30(5):3917-3924. DOI: 10.1007/s00520-021-06751-3Hoyle E., Kilbreath S., Dylke E. Body image and sexuality concerns in women with breast cancer-related lymphedema: a cross-sectional study. Support Care Cancer. 2022;30(5):3917-3924. DOI: 10.1007/s00520-021-06751-3Poręba M., Gać P., Usnarska-Zubkiewicz L., Pilecki W., Kuliczkowski K., Mazur G., Sobieszczanska M., Poręba R. The analysis of the parameters of 24-hr ECG Holter monitoring in patients with blood neoplasms undergoing high-dose chemotherapy and stem cell transplantation. Ann. Noninvasive Electrocardiol. 2018;23(4):e12534. DOI: 10.1111/anec.12534Poręba M., Gać P., Usnarska-Zubkiewicz L., Pilecki W., Kuliczkowski K., Mazur G., Sobieszczanska M., Poręba R. The analysis of the parameters of 24-hr ECG Holter monitoring in patients with blood neoplasms undergoing high-dose chemotherapy and stem cell transplantation. Ann. Noninvasive Electrocardiol. 2018;23(4):e12534. DOI: 10.1111/anec.12534Петровский А.В., Чжан Л., Соболевский В.А., Крохина О.В., Валиев Р.К., Нечушкин М.И., Амосова В.А. Качество жизни у больных мультицентрическим раком молочной железы. Злока-чественные опухоли. 2020;10(1):21-28. DOI: 10.18027/2224-5057-2020-10-1-21-28Petrovsky A.V., Zhang L., Sobolevsky V.A., Krokhina O.V., Valiev R.K., Nechushkin M.I., Amosova V.A. Quality of life in patients with multicentric breast cancer. Malignant tumors. 2020;10(1):21-28. (In Russian). DOI: 10.18027/2224-5057-2020-10-1-21-28Gonzalez L., Bardach A., Palacios A., Peckaitis C., Ciapponi A., Pichón-Riviere A., Augustovski F., Health-related quality of life in patients with breast cancer in latin america and the caribbean: a systematic review and meta-analysis. The Oncologist. 2021;26(5);794-806. DOI: 10.1002/onco.13709Gonzalez L., Bardach A., Palacios A., Peckaitis C., Ciapponi A., Pichón-Riviere A., Augustovski F., Health-related quality of life in patients with breast cancer in latin america and the caribbean: a systematic review and meta-analysis. The Oncologist. 2021;26(5);794-806. DOI: 10.1002/onco.13709de Ligt K.M., Heins M., Verloop J., Ezendam N.P.M., Smorenburg C.H., Korevaar J.C., Siesling S. The impact of health symptoms on health-related quality of life in early-stage breast cancer survivors. Breast Cancer Res. Treat. 2019;178(3):703-711. DOI: 10.1007/s10549-019-05433-3de Ligt K.M., Heins M., Verloop J., Ezendam N.P.M., Smorenburg C.H., Korevaar J.C., Siesling S. The impact of health symptoms on health-related quality of life in early-stage breast cancer survivors. Breast Cancer Res. Treat. 2019;178(3):703-711. DOI: 10.1007/s10549-019-05433-3Ośmiałowska E., Staś J., Chabowski M., Jankowska-Polańska B. Illness Perception and Quality of Life in Patients with Breast Cancer. Cancers (Basel). 2022;14(5):1214. DOI: 10.3390/cancers14051214Ośmiałowska E., Staś J., Chabowski M., Jankowska-Polańska B. Illness Perception and Quality of Life in Patients with Breast Cancer. Cancers (Basel). 2022;14(5):1214. DOI: 10.3390/cancers14051214Gebert P., Dordevic A.D., Roehle R., Hage A.M., Karsten M.M. Data of real-world reference scores for EORTC QLQ-C30 and QLQ-BR23 at baseline in women with early breast cancer and other breast diseases. Data Brief. 2022;43:108347. DOI: 10.1016/j.dib.2022.108347Gebert P., Dordevic A.D., Roehle R., Hage A.M., Karsten M.M. Data of real-world reference scores for EORTC QLQ-C30 and QLQ-BR23 at baseline in women with early breast cancer and other breast diseases. Data Brief. 2022;43:108347. DOI: 10.1016/j.dib.2022.108347Krohe M., Hao Y., Lamoureux R.E. et al. Patient-reported outcomes in metastatic breast cancer: a review of industry-sponsored clinical trials. Breast Cancer: Basic and Clinical Research. 2016;10:93-102. DOI: 10.4137/bcbcr.s39385Krohe M., Hao Y., Lamoureux R.E. et al. Patient-reported outcomes in metastatic breast cancer: a review of industry-sponsored clinical trials. Breast Cancer: Basic and Clinical Research. 2016;10:93-102. DOI: 10.4137/bcbcr.s39385Dent S., Moore H., Raval P. et al. How to manage and monitor cardiac dysfunction in patients with metastatic her2-positive breast cancer. J. Am. Coll. Cardiol. CardioOnc. 2022;4(3);404-408. DOI: 10.1016/j.jaccao.2022.06.002Dent S., Moore H., Raval P. et al. How to manage and monitor cardiac dysfunction in patients with metastatic her2-positive breast cancer. J. Am. Coll. Cardiol. CardioOnc. 2022;4(3);404-408. DOI: 10.1016/j.jaccao.2022.06.002Rositch A.F., Unger-Saldana K., DeBoer R.J., Ng'ang'a A., Weiner B.J. The role of dissemination and implementation science in global breast cancer control programs: Frameworks, methods, and examples. Cancer. 2020;126(10);2394-404. DOI: 10.1002/cncr.32877Rositch A.F., Unger-Saldana K., DeBoer R.J., Ng'ang'a A., Weiner B.J. The role of dissemination and implementation science in global breast cancer control programs: Frameworks, methods, and examples. Cancer. 2020;126(10);2394-404. DOI: 10.1002/cncr.32877

The authors declare that there are no conflicts of interest present.